1. Clinical Characteristics, Comorbidities, and Outcomes Among Patients With COVID-19 Hospitalized in the NYC Area
2. Diagnosis / Management
2.1. Clinical
2.1.1. Symptoms
2.1.1.1. Disease Progression
2.1.1.1.1. Comorbidities
2.1.1.2. Cardiac
2.1.1.2.1. https://khn.org/news/mysterious-heart-damage-not-just-lung-troubles-befalling-covid-19-patients/
2.1.1.3. Expanded Case Definition
2.1.1.3.1. The Washington Post: CDC confirms six coronavirus symptoms showing up in patients over and over. https://www.washingtonpost.com/health/2020/04/27/six-new-coronavirus-symptoms/
2.1.2. Where all do we have ACE2 Receptors?
2.1.2.1. Angiotensin-converting enzyme 2 - Wikipedia
2.1.2.2. Lungs
2.1.2.3. Heart
2.1.2.4. Arteries
2.1.2.5. Intestines
2.1.2.6. Where else?
2.1.2.7. Inhibition
2.1.2.7.1. rhACE2?
2.1.2.8. How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes
2.1.2.9. It's ok to continue BP medication
2.1.2.9.1. https://jamanetwork.com/journals/jama/fullarticle/2767669
2.1.3. Signs
2.1.3.1. Red itchy eyes / conjunctivitis
2.1.4. Tests / Biomarkers of severe disease
2.1.4.1. https://pubmed.ncbi.nlm.nih.gov/32286245/
2.1.5. Pathophysiology
2.1.5.1. URTI
2.1.5.2. LRTI
2.1.5.2.1. CT Lung https://www.ncbi.nlm.nih.gov/pubmed/?term=32053470
2.1.5.2.2. Type L / Type H Pneumonia?
2.1.5.2.3. CPAP vs BiPAP (information)
2.1.5.2.4. Breathing mechanics
2.1.5.3. GI
2.1.5.3.1. https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30083-2/fulltext
2.1.5.4. Cardiac / Lung / Kidney
2.1.5.4.1. https://www.ahajournals.org/doi/10.1161/JAHA.120.016219
2.1.5.5. ARDS
2.1.5.5.1. How accurate are the Phenotypes?
2.1.5.6. Atypical ARDS?
2.1.5.6.1. https://www.youtube.com/watch?v=U5cvPwh_vtM&t=8s
2.1.5.6.2. Hypoxemia
2.1.5.6.3. See also HCQ Bubble
2.1.5.6.4. Different phenotypes - Italian experience
2.1.5.7. Coagulopathies / DIC?
2.1.5.7.1. Coagulation Abnormalities in COVID 19 Patients
2.1.5.7.2. Why?
2.1.5.8. Microangiopathy in the lung
2.1.5.8.1. https://www.nejm.org/doi/full/10.1056/NEJMoa2015432?query=C19&cid=DM92296_Catalyst_Subscriber&bid=201860269
2.1.5.9. Derm
2.1.5.9.1. Covid Toes
2.1.5.10. ACE2 Mediated Vascoconstriction?
2.1.5.10.1. A Theoretical Model of the Pathophysiology of COVID-19 with Farid Jalali
2.1.5.11. HR monitors
2.1.5.11.1. https://www.medscape.com/viewarticle/934496
2.1.5.12. Inflammatory Cascade / Markers
2.1.5.12.1. https://news.kaist.ac.kr/newsen/html/news/?mode=V&mng_no=9951
2.1.6. Risk Factors
2.1.6.1. https://pubmed.ncbi.nlm.nih.gov/32232218/
2.1.6.2. Comorbidities
2.1.7. COVID-19 | Corona Virus: Epidemiology, Pathophysiology, Diagnostics
2.1.7.1. As of March 15th
2.1.8. NEJM
2.1.8.1. https://www.nejm.org/coronavirus
2.1.8.2. Case Study - Long Term Health Care Facility - Washington State
2.1.8.2.1. https://www.nejm.org/doi/full/10.1056/NEJMoa2005412?cid=DM89287_Catalyst_COVID-19_Newsletter&bid=174243764
2.1.9. Lancet
2.1.10. Predisposition to severe disease symptoms
2.1.10.1. https://jamanetwork.com/journals/jamacardiology/fullarticle/2763845
2.1.10.2. Inflammation as a modifier?
2.1.10.2.1. Any correlations with hs-CRP?
2.1.11. Social Determinants
2.1.11.1. https://www.beckershospitalreview.com/data-analytics/ucsf-launches-dashboard-to-track-how-social-determinants-affect-population-health.html
2.1.11.2. https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2020.00598?utm_campaign=HASU+5-24-20&utm_medium=email&utm_content=COVID-19%3A+Disparities+In+Outcomes%2C+Primary+Care%2C+Remdesivir%3B+ACA+Round-Up%3B+Health+Insurance+Surcharges+For+Tobacco+Use%3B+Reimagining+Involuntary+Commitment&utm_source=Newsletter
2.1.11.2.1. Why are people of color disproportionately susceptible to severer outcomes?
2.1.12. MMWR June 16
2.1.12.1. https://www.cdc.gov/mmwr/volumes/69/wr/mm6924e2.htm
2.1.13. Autopsy Results in severe Covid
2.1.13.1. https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(20)30144-0/fulltext
2.1.14. Repeat Infections?
2.1.14.1. Covid reinfection: Man gets Covid twice and second hit 'more severe'
2.1.14.1.1. Ho
2.2. Testing
2.2.1. NAAT
2.2.1.1. RT-PCR
2.2.1.1.1. N Segment
2.2.1.1.2. Other segments
2.2.1.1.3. https://youtu.be/C1t3SoR8fwg
2.2.1.2. IIT Probe less Dx - https://www.linkedin.com/posts/activity-6647392190601539584-zv0l - POC
2.2.2. Serological
2.2.2.1. IgM
2.2.2.2. IgG
2.2.3. ALT predictor of severe lung complications?
2.2.3.1. https://www.france24.com/en/20200330-ai-tool-predicts-which-coronavirus-patients-get-deadly-wet-lung
2.2.3.2. https://en.wikipedia.org/wiki/Alanine_transaminase
2.2.4. CRISPR
2.2.4.1. India
2.2.4.1.1. Feluda - https://theprint.in/science/satyajit-rays-feluda-will-soon-detect-coronavirus-in-minutes-thanks-to-csir-scientists/404057/
2.2.5. Rapid Biosensor S Korea
2.2.5.1. https://pubs.acs.org/doi/10.1021/acsnano.0c02823
3. Data Sources
3.1. JHU
3.1.1. https://coronavirus.jhu.edu/
3.1.2. Github
3.1.2.1. https://github.com/CSSEGISandData/COVID-19
3.2. FDA Covid FAQs
3.2.1. Coronavirus Disease 2019 (COVID-19) Frequently Asked Questions
3.3. The Covid Handbook - China
3.3.1. PDF
3.4. Prevalence
3.4.1. NYC
3.4.1.1. https://www.nejm.org/doi/full/10.1056/NEJMc2009316?fbclid=IwAR1JU20xBGOuad0UDREUjGb1Kpj1VQ0ypbkwL_GheeFr15rvREpxEwuSBqg
3.4.1.1.1. "Of the 211 women without symptoms, all were afebrile on admission. Nasopharyngeal swabs were obtained from 210 of the 211 women (99.5%) who did not have symptoms of Covid-19; of these women, 29 (13.7%) were positive for SARS-CoV-2. Thus, 29 of the 33 patients who were positive for SARS-CoV-2 at admission (87.9%) had no symptoms of Covid-19 at presentation."
3.4.2. Santa Clara County
3.4.2.1. COVID-19 Antibody Seroprevalence in Santa Clara County, California
3.4.2.1.1. "Under the three scenarios for test performance characteristics, the population prevalence of COVID-19 in Santa Clara ranged from 2.49% (95CI 1.80-3.17%) to 4.16% (2.58-5.70%)."
3.5. Napkin iFR
3.5.1. Preliminary CFR - Covid
3.6. California
3.6.1. https://public.tableau.com/views/COVID-19PublicDashboard/Covid-19Public?:embed=y&:display_count=no&:showVizHome=no
3.7. YouTube
3.7.1. covid - YouTube
3.8. Case Definition CDC April 14th
3.8.1. Coronavirus Disease 2019 (COVID-19) in the U.S.
3.8.2. To include Probable Cases and Probable Deaths
3.8.3. CDC Cases in the US
3.8.3.1. Coronavirus Disease 2019 (COVID-19) in the U.S.
3.9. R Packages and Shiny Apps
3.9.1. https://towardsdatascience.com/top-5-r-resources-on-covid-19-coronavirus-1d4c8df6d85f
3.9.1.1. Covid19 DataHub
3.9.1.1.1. covid19datahub/COVID19
3.10. CDC
3.10.1. Scenario Planning
3.10.1.1. https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html
3.11. UC Clinical
3.11.1. https://www.healthcareitnews.com/news/uc-health-creates-unified-data-set-aid-covid-19-researchers
3.12. Mobility and Case Numbers
3.12.1. https://transportfindings.org/article/12976-using-google-community-mobility-reports-to-investigate-the-incidence-of-covid-19-in-the-united-states
3.13. Excess Mortality
3.13.1. https://ourworldindata.org/covid-excess-mortality
4. Epidemiological Concepts
4.1. R0 (Reproductive Ratio)
4.1.1. Basic Reproduction Number, R0
4.2. Stages of Spread
4.3. SIR Model
4.3.1. https://youtu.be/Qrp40ck3WpI
4.3.2. https://youtu.be/uSLFudKBnBI
5. Legend
5.1. Anecdotal
5.2. Re-purposed Approaches
5.3. Hypotheses
5.4. Adjuvants
5.5. In development
5.6. Very Important
6. Idea Hacking
6.1. https://docs.google.com/document/d/1rVz-GPtF2ek-8V2sZcZPPfL6ocXqtCUEWFEwiDp-7_Y/edit?usp=drivesdk
6.2. MUSC Mask w/ HEPA
6.2.1. https://web.musc.edu/innovation/covid-19-innovation
6.3. Czech Face Shield Design
6.3.1. https://www.prusa3d.com/covid19/
7. Surveillance
7.1. Waste Water
7.1.1. https://www.bloomberg.com/news/articles/2020-03-31/coronavirus-in-sewage-portended-covid-19-outbreak-in-dutch-city
7.2. Recurrence?
7.2.1. Can you get re-infected with coronavirus?
7.3. Santa Clara Study
7.4. NY maternity Study
7.5. India's Delhi Food Worker Study
7.6. NY City Surveillance
8. Questions / Hypotheses
8.1. Is genetic diversity more resilient to developing severe forms of covid19 at a population level?
8.2. Virus particles are small - they replicate fast - as part of replication they damage cells - they then enter adjacent cells - they basically over time will make their own access route. It seems some strains replicate faster than other ones, and so they will be the ones I'm guessing that are causing more of the non lung / non intestinal issues?
8.3. Background inflammation relevant? hsCRP?
8.4. Nicotine / Smoking?
8.4.1. https://theprint.in/health/nicotine-patch-test-on-covid-patients-healthcare-workers-to-see-if-smokers-are-protected/413513/
9. India
9.1. The Bhilwara Model
9.1.1. https://www.mohfw.gov.in/pdf/3ContainmentPlanforLargeOutbreaksofCOVID19Final.pdf
9.2. National Covid Trajectory
9.2.1. National Covid Trajectory - India
10. How to Protect MeS Individuals?
11. Prevention
11.1. Social distancing
11.1.1. Self imposed
11.1.2. State imposed
11.2. Prevention Strategies
11.2.1. Disinfection
11.2.1.1. Alcohol Based
11.2.1.2. Hydrogen Peroxide
11.2.1.2.1. Vapor phase
11.2.1.3. Chlorine Based
11.2.1.3.1. Na Hypochlorite
11.2.1.4. Non contact
11.2.1.4.1. UV light
11.2.1.4.2. Negative Ions
11.2.1.5. EPA - Surface Disinfectants - List N
11.2.1.5.1. List N: Disinfectants for Use Against SARS-CoV-2 | US EPA
11.2.2. Boost Immunity
11.2.2.1. BCG vaccine
11.2.2.1.1. https://www.sciencemag.org/news/2020/03/can-century-old-tb-vaccine-steel-immune-system-against-new-coronavirus
11.2.2.1.2. Pharmaceutical Technology: BCG vaccination may induce heterologous immunity and protect against Covid-19. https://www.pharmaceutical-technology.com/comment/bcg-vaccination-covid-19/
11.2.2.2. Convalescent Plasma
11.2.2.3. Nutrition / Sleep / Exercise
11.2.2.4. Vitamin D ?
11.2.2.4.1. https://youtu.be/GCSXNGc7pfs
11.2.2.4.2. https://www.ncbi.nlm.nih.gov/pubmed/32252338
11.2.2.4.3. https://clinicaltrials.gov/ct2/show/NCT04334005
11.2.2.4.4. https://www.hopkinsmedicine.org/health/wellness-and-prevention/vitamin-d-and-calcium
11.2.2.4.5. https://www.medrxiv.org/content/10.1101/2020.04.08.20058578v3
11.2.3. Personal Hygiene
11.2.4. Contact Tracing
11.2.4.1. https://www.npr.org/sections/health-shots/2020/04/21/840539685/cdc-to-fund-650-health-experts-to-help-states-trace-stop-covid-19
11.3. Immunization
11.3.1. Vaccine
11.3.1.1. J & J
11.3.1.1.1. https://www.forbes.com/sites/thomasbrewster/2020/03/30/the-us-just-signed-a-450-million-coronavirus-vaccine-contract-with-johnson--johnson/
11.3.1.2. https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins
11.3.1.2.1. Phase 1 Kaiser
11.3.1.3. PittCoVacc
11.3.1.3.1. https://www.independent.co.uk/news/science/coronavirus-vaccine-pittsburgh-university-lancet-study-covid-pandemic-a9442536.html
11.3.1.4. Chadox1
11.3.1.4.1. https://www.vaccitech.co.uk/technology/
11.3.1.4.2. http://www.ox.ac.uk/news/2020-04-23-oxford-covid-19-vaccine-begins-human-trial-stage#
11.3.1.4.3. Timeline
11.3.1.4.4. Phase i/ii
11.3.1.5. mRNA
11.3.1.5.1. Moderna
11.3.1.5.2. Summer Phase III Trials
11.3.1.6. CanSino
11.3.1.6.1. https://www.reuters.com/article/us-health-coronavirus-china-vaccine-idUSKBN2400DZ
11.3.1.6.2. Phase ii
11.3.1.7. CoVaxin (Bharat Biotech)
11.3.1.7.1. https://theprint.in/health/all-about-bharat-biotechs-covaxin-indias-first-indigenous-covid-vaccine-candidate/455028/
11.3.2. Convalescent Plasma
11.3.2.1. http://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds
11.3.2.2. JHU - Immunization of Healthcare Workers - http://foxbaltimore.com/news/coronavirus/fda-approves-trial-for-coronavirus-therapy-at-johns-hopkins-university
11.3.2.3. Antibody Titres in Convalescent Plasma
11.3.2.3.1. https://www.medrxiv.org/content/10.1101/2020.06.08.20124792v1
11.3.2.4. D614G Mutation and reduced antisera neutralization
11.3.2.4.1. https://www.biorxiv.org/content/10.1101/2020.06.20.161323v1
11.3.3. What is immunity
11.3.3.1. Immune System: Innate and Adaptive Immunity Explained
11.3.3.2. T cell Mediated
11.3.3.2.1. https://directorsblog.nih.gov/2020/07/28/immune-t-cells-may-offer-lasting-protection-against-covid-19/
11.4. LAV
11.4.1. https://theprint.in/health/in-a-first-india-us-pharma-majors-join-hands-to-develop-covid-19-vaccine/397334/
11.5. Nutrition - As anti inflammatory
11.5.1. https://www.mdpi.com/2072-6643/12/5/1466/htm
11.5.1.1. Vit D / C + Zinc + Fiber
11.6. Seroconversion = Immunity?
11.6.1. https://www.medrxiv.org/content/10.1101/2020.05.19.20101832v2
12. Treatment
12.1. Symptomatic
12.1.1. ARDS or Atypical ARDS
12.1.1.1. Ventilators
12.1.1.1.1. Low cost ventilators
12.1.1.1.2. General Motors
12.1.1.2. O2 hoods
12.1.1.2.1. https://erj.ersjournals.com/content/early/2020/04/16/13993003.01017-2020
12.1.2. GI
12.1.3. Non-ARDS
12.2. Pharmacological
12.2.1. Anti-virals
12.2.1.1. Favipiravir
12.2.1.1.1. https://fortune.com/2020/03/28/coronavirus-treatment-drug-antiviral-favipiravir-avigan-fujifilm/
12.2.1.1.2. Link to Chinese study?
12.2.1.2. Remdesivir
12.2.1.2.1. https://www.fiercebiotech.com/biotech/gilead-supersizes-remdesivir-trials-changes-primary-endpoint
12.2.1.2.2. SoC according to Fauci as of 4/29
12.2.1.3. Lopinavir? Probably Not?
12.2.1.3.1. https://theprint.in/health/hiv-drug-combo-touted-as-a-promising-covid-19-treatment-fails-clinical-trial/405959/
12.2.2. HCQ / Chloroquine
12.2.2.1. FDA Emergency Authorization - https://www.politico.com/news/2020/03/29/fda-emergency-authorization-anti-malaria-drug-155095
12.2.2.2. Haem metabolism
12.2.2.2.1. https://chemrxiv.org/articles/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173
12.2.2.3. IHU - Mediterranean Infection
12.2.2.3.1. Pré-Prints IHU – IHU
12.2.2.4. VA Study - Contraindicated in those over 70?
12.2.2.4.1. https://www.medrxiv.org/content/10.1101/2020.04.16.20065920v1.full.pdf
12.2.3. Others
12.2.3.1. Azithromycin
12.2.4. ACE2 Receptor Blockers?
12.2.4.1. http://www.infectioncontroltoday.com/covid-19/evidence-continues-link-ace-inhibitors-severe-covid-19-symptoms
12.2.4.2. How to treat those with hypertension?
12.2.4.3. Jacob Glanville on LinkedIn: #COVID19 #therapeutic #neutralizing | 103 comments
12.2.4.4. ACE2 Receptor
12.2.4.4.1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=AGTR1&keywords=ACE2,Receptor
12.2.5. hsp90 inhibition?
12.2.5.1. Drug Repositioning Suggests a Role for the Heat Shock Protein 90 Inhibitor Geldanamycin in Treating COVID-19 Infection
12.2.5.2. What else inhibits hsp90?
12.2.5.2.1. curcumin
12.2.6. TMPRSS2 Inhibition
12.2.6.1. https://www.dpz.eu/en/home/single-view/news/die-vermehrung-von-sars-coronavirus-2-im-menschen-verhindern.html
12.2.6.2. Genetic Expression of ..
12.2.6.2.1. https://www.medrxiv.org/content/10.1101/2020.03.30.20047878v1.full.pdf
12.2.7. Anti-coagulants
12.2.7.1. https://www.eurekalert.org/pub_releases/2020-05/tmsh-btm050420.php
12.2.8. Ivermectin?
12.2.8.1. https://www.sciencedirect.com/science/article/pii/S0166354220302011
12.2.8.2. Ivermectin and Doxy being used in Bangladesh
12.2.9. IL-6 Inhibition
12.2.9.1. https://www.technologyreview.com/2020/06/03/1002650/antibody-drug-tocilizumab-immune-response-covid-19-saves-lives/
12.3. Immunological
12.3.1. Convalescent Plasma
12.3.1.1. http://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds
12.3.1.2. https://jamanetwork.com/journals/jama/fullarticle/2763983
12.3.1.3. https://www.bizjournals.com/philadelphia/news/2020/04/06/montco-firm-forms-alliance-to-develop-coronavirus.html
12.3.1.4. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/donate-covid-19-plasma
12.3.1.5. Michigan State Convalescent Plasma Project
12.3.1.5.1. National COVID-19 Convalescent Plasma Project
12.3.1.5.2. Key Scientific Papers
12.3.1.6. FDA Recommendations
12.3.1.6.1. Investigational COVID-19 Convalescent Plasma - Emergency INDs
12.3.2. Monoclonal Antibodies
12.3.2.1. https://www.npr.org/sections/health-shots/2020/03/26/822003826/how-monoclonal-antibodies-might-prove-useful-against-the-coronavirus
12.3.3. Immunomodulators
12.3.3.1. Sepsivac / India
12.3.3.1.1. CSIR to test sepsis drug in asymptomatic Covid patients and those who have recovered
12.4. Stem Cells?
12.4.1. Miomir's LI Post
12.4.1.1. https://www.linkedin.com/posts/miomir-knezevic-5a79613_novel-approach-to-treating-terminal-stage-activity-6648598562789736450-nePZ
12.5. Nutrition
12.5.1. Clinical Considerations
12.5.1.1. Pg 30 - Handbook of Covid-19 Prevention and Treatment, Zhejiang University School of Medicine.
12.5.1.1.1. Prevention of Regurgitation and Aspiration - Gastric residual volume and gastrointestinal function should be routinely evaluated. Appropriate enteral nutrition is recommended to be given as earlier as possible. Nasointestinal feeding and continuous nasogastric decompression are recommended. Enteral nutrition should be suspended and aspiration with 50 mL syringe be done before transfer. If no contraindication exists, a 30° semi-sitting position is recommended
12.5.1.1.2. Fluid Management - Excessive fluid burden worsens hypoxemia in COVID-19 patients. To reduce pulmonary exudation and improve oxygenation, the amount of fluid should be strictly controlled while ensuring the patient's perfusion.
12.5.1.1.3. GI Considerations
12.6. WHO Solidarity Trial
12.6.1. https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments
13. Models / Literature
13.1. Italian SIDR Model
13.1.1. Data-based analysis, modelling and forecasting of the COVID-19 outbreak
13.2. DoD Model for information evolution
13.2.1. https://www.pnas.org/content/117/11/5664
13.3. IHME
13.3.1. https://covid19.healthdata.org/united-states-of-america
14. Patient Flow
14.1. I'm having difficulty breathing
14.1.1. emergency.fyi
14.1.2. Kaiser
14.2. I have symptoms
14.2.1. CDPH
14.2.1.1. California Department of Public Health
14.3. Monitor Pulse Ox Levels
14.3.1. Cutoff?
14.3.1.1. 90%?
14.3.1.2. 95%?
15. Equipment
15.1. PPE
15.1.1. Facial Masks
15.1.1.1. Reusable
15.1.1.1.1. Elastomeric
15.1.1.1.2. Non soiled N95
15.1.1.2. Disposable
15.1.1.2.1. Surgical
15.1.1.2.2. N95
15.1.2. Shields
15.1.3. Gowns
15.1.4. Gloves
15.1.5. Booties
15.1.6. Suits
15.1.7. PAPR - Another bottle neck
15.1.7.1. A must for invasive ventilation?
15.1.8. Suppliers - PPE / Serology Tests
15.1.8.1. Global - Sourced From China
15.1.8.1.1. Prices as of March 27th
15.1.8.2. Local India PPE / Sanitizer
15.1.8.2.1. Rnexports@hotmail.com
15.2. Ventillators
15.3. Plasmaphaeresis
15.4. CPAP
15.4.1. Italy
15.4.1.1. CPAP with Helmets
15.4.1.1.1. https://www.uchicagomedicine.org/forefront/patient-care-articles/helmet-based-ventilation-is-superior-to-face-mask-for-patients-with-respiratory-distress
15.4.2. What is CPAP?
15.4.2.1. What's the Difference Between a CPAP, APAP, and BiPAP Machine?
16. Virus Morphology
16.1. Mutation
16.1.1. https://youtu.be/FYPZHA-UjUY
16.1.2. Antigenic Shift - Influenza
16.1.2.1. https://youtu.be/tMTl3gU0mFc
16.1.3. Tracking the different strains
16.1.3.1. https://nextstrain.org/
16.1.4. India
16.1.4.1. No need to panic, COVID-19 is something we can easily conquer: Padma Bhushan Dr D Nageshwar Reddy
16.1.5. Super virulent strains?
16.1.5.1. https://www.scmp.com/news/china/science/article/3080771/coronavirus-mutations-affect-deadliness-strains-chinese-study
16.1.6. S1 D614G
16.1.6.1. https://www.biorxiv.org/content/10.1101/2020.04.29.069054v2
16.2. Replication Cycle
16.2.1. https://youtu.be/zvuYJTL90J8
16.3. Coronaviruses
16.3.1. Coronaviruses 101: Focus on Molecular Virology
16.4. Seasonality?
16.4.1. https://www.cidrap.umn.edu/news-perspective/2020/04/experts-covid-19-pandemic-unlikely-ebb-weather-warms
16.5. ReplicationKinetics
16.5.1. Kinetic Modeling of Virus Growth in Cells
16.6. Glycan Shield on S Protein
16.6.1. https://pubs.acs.org/doi/10.1021/acscentsci.0c01056
17. Disaggregate News Reports
17.1. https://theprint.in/health/pancreatitis-drug-trials-to-a-wastewater-test-for-tracking-virus-top-research-on-covid-19/391990/
18. Sequelae
18.1. Parkinsonism
18.1.1. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30305-7/fulltext
19. Italy
19.1. Vo
19.1.1. https://www.medrxiv.org/content/10.1101/2020.04.17.20053157v1
20. Milestones
20.1. 4/30
20.1.1. Korea confirms reinfections aren't taking place
20.1.2. Remdesivir becomes SoC in the US
20.1.2.1. Next step is Remdesivir + Monoclonal Antibodies